After having already sequenced thousands of cancer genes in projects together, the Yale School of Medicine and Gilead announced they will continue their partnership to find therapeutic candidates for cancer for an additional three years.
After having already sequenced thousands of cancer genes in projects together, the Yale School of Medicine and Gilead announced they will continue their partnership to find therapeutic candidates for cancer for an additional three years. The original agreement was forged in 2011 and can be renewed for up to 10 years.
Under the terms of the agreement, Gilead will provide $30 million more in funding for research support, and in return, will get licensing rights for any inventions that result from the collaboration. The goal of the work is to discover novel targeted therapies, especially for patients who have developed drug resistance to first-line therapies. Of particular interest is the discovery of a single therapy that could be used in multiple different cancers.
“The pace of scientific exchange and innovation spurred by our work together is unlike anything I have seen before,” remarked Joseph Schlessinger, PhD, William H. Prusoff Professor, chair of the Department of Pharmacology, and director of the Cancer Biology Institute at Yale West Campus, in a press release. “If our accomplishments over the past three years are any indication, we are confident that our future endeavors will significantly advance our current understanding and treatment of cancer.”
Source:
Yale
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.